全文获取类型
收费全文 | 33936篇 |
免费 | 2475篇 |
国内免费 | 117篇 |
专业分类
耳鼻咽喉 | 445篇 |
儿科学 | 881篇 |
妇产科学 | 736篇 |
基础医学 | 4569篇 |
口腔科学 | 2731篇 |
临床医学 | 2706篇 |
内科学 | 7299篇 |
皮肤病学 | 846篇 |
神经病学 | 2708篇 |
特种医学 | 918篇 |
外国民族医学 | 6篇 |
外科学 | 4045篇 |
综合类 | 248篇 |
一般理论 | 8篇 |
预防医学 | 3928篇 |
眼科学 | 484篇 |
药学 | 2135篇 |
中国医学 | 247篇 |
肿瘤学 | 1588篇 |
出版年
2023年 | 238篇 |
2022年 | 286篇 |
2021年 | 1023篇 |
2020年 | 785篇 |
2019年 | 1031篇 |
2018年 | 1283篇 |
2017年 | 921篇 |
2016年 | 968篇 |
2015年 | 1115篇 |
2014年 | 1479篇 |
2013年 | 1714篇 |
2012年 | 2514篇 |
2011年 | 2673篇 |
2010年 | 1445篇 |
2009年 | 1103篇 |
2008年 | 1882篇 |
2007年 | 2008篇 |
2006年 | 1604篇 |
2005年 | 1545篇 |
2004年 | 1366篇 |
2003年 | 1213篇 |
2002年 | 1019篇 |
2001年 | 769篇 |
2000年 | 709篇 |
1999年 | 650篇 |
1998年 | 217篇 |
1997年 | 178篇 |
1996年 | 139篇 |
1995年 | 153篇 |
1994年 | 154篇 |
1993年 | 143篇 |
1992年 | 390篇 |
1991年 | 349篇 |
1990年 | 310篇 |
1989年 | 320篇 |
1988年 | 295篇 |
1987年 | 227篇 |
1986年 | 243篇 |
1985年 | 233篇 |
1984年 | 155篇 |
1983年 | 134篇 |
1982年 | 82篇 |
1979年 | 138篇 |
1978年 | 100篇 |
1975年 | 84篇 |
1974年 | 82篇 |
1973年 | 98篇 |
1970年 | 90篇 |
1969年 | 101篇 |
1968年 | 81篇 |
排序方式: 共有10000条查询结果,搜索用时 18 毫秒
1.
2.
Carlton Corinne N. Garcia Katelyn M. Andino Mara Villalongo Ollendick Thomas H. Richey John A. 《Cognitive therapy and research》2022,46(5):916-926
Cognitive Therapy and Research - Individuals with Social Anxiety Disorder (SAD) may be at a higher risk for negative outcomes during the COVID-19 pandemic due to isolation that is both... 相似文献
3.
Cheryl L. Rock PhD RD Cynthia A. Thomson PhD RD Kristen R. Sullivan MS MPH Carol L. Howe MD MLS Lawrence H. Kushi ScD Bette J. Caan DrPH Marian L. Neuhouser PhD RD Elisa V. Bandera MD PhD Ying Wang PhD Kimberly Robien PhD RD Karen M. Basen-Engquist PhD MPH Justin C. Brown PhD Kerry S. Courneya PhD Tracy E. Crane PhD RDN David O. Garcia PhD FACSM Barbara L. Grant MS RDN CSO FAND Kathryn K. Hamilton MA RDN CSO CDN FAND Sheri J. Hartman PhD Stacey A. Kenfield ScD Maria Elena Martinez PhD Jeffrey A. Meyerhardt MD MPH Larissa Nekhlyudov MD MPH Linda Overholser MD Alpa V. Patel PhD Bernardine M. Pinto PhD Mary E. Platek PhD RD CDN Erika Rees-Punia PhD MPH Colleen K. Spees PhD MEd RD LD FAND Susan M. Gapstur PhD Marjorie L. McCullough ScD RD 《CA: a cancer journal for clinicians》2022,72(3):230-262
The overall 5-year relative survival rate for all cancers combined is now 68%, and there are over 16.9 million survivors in the United States. Evidence from laboratory and observational studies suggests that factors such as diet, physical activity, and obesity may affect risk for recurrence and overall survival after a cancer diagnosis. The purpose of this American Cancer Society guideline is to provide evidence-based, cancer-specific recommendations for anthropometric parameters, physical activity, diet, and alcohol intake for reducing recurrence and cancer-specific and overall mortality. The audiences for this guideline are health care providers caring for cancer survivors as well as cancer survivors and their families. The guideline is intended to serve as a resource for informing American Cancer Society programs, health policy, and the media. Sources of evidence that form the basis of this guideline are systematic literature reviews, meta-analyses, pooled analyses of cohort studies, and large randomized clinical trials published since 2012. Recommendations for nutrition and physical activity during cancer treatment, informed by current practice, large cancer care organizations, and reviews of other expert bodies, are also presented. To provide additional context for the guidelines, the authors also include information on the relationship between health-related behaviors and comorbidities, long-term sequelae and patient-reported outcomes, and health disparities, with attention to enabling survivors' ability to adhere to recommendations. Approaches to meet survivors' needs are addressed as well as clinical care coordination and resources for nutrition and physical activity counseling after a cancer diagnosis. 相似文献
4.
Naveen Pemmaraju MD Jacqueline S. Garcia MD Andrew Perkins MBBS PhD Jason G. Harb PhD Andrew J. Souers PhD Michael E. Werner PhD Christopher M. Brown PhD Francesco Passamonti MD 《Cancer》2023,129(22):3535-3545
Myelofibrosis is a heterogeneous myeloproliferative neoplasm characterized by chronic inflammation, progressive bone marrow failure, and hepatosplenic extramedullary hematopoiesis. Treatments like Janus kinase inhibitor monotherapy (e.g., ruxolitinib) provide significant spleen and symptom relief but demonstrate limited ability to lead to a durable disease modification. There is an urgent unmet medical need for treatments with a novel mechanism of action that can modify the underlying pathophysiology and affect the disease course of myelofibrosis. This review highlights the role of B-cell lymphoma (BCL) protein BCL-extra large (BCL-XL) in disease pathogenesis and the potential role that navitoclax, a BCL-extra large/BCL-2 inhibitor, may have in myelofibrosis treatment. 相似文献
5.
Penelas Alice Gonçalves da Silva Eduardo Moreira Fedozzi Julia Mattos Alves Amanda Cypriano Orem Paulo Roberto Barros Poskus Laiza Tatiana Feitosa Victor Pinheiro Guimarães José Guilherme Antunes 《Odontology / the Society of the Nippon Dental University》2022,110(3):569-576
Odontology - This study aimed at evaluating the influence of glass-fiber post (GFP) relining with composites of different opacities on resin cement layer thickness (CLT), bond strength (BS) to root... 相似文献
6.
Glutathione S-transferase Polymorphisms in Head and Neck Squamous Cell Carcinoma Treated with Chemotherapy and/or Radiotherapy 下载免费PDF全文
Mauricio Pereira ManigliaAnelise RussoPatrícia Matos Biselli-ChicoteJuliana Garcia de Oliveira-CucoloGabriela Helena Rodrigues-Flemingjosé Victor -ManigliaÉrika Cristina PavarinoEny Maria Goloni-Bertollo 《Asian Pacific journal of cancer prevention》2020,21(6):1637-1644
Background/Aim: The Glutathione S-transferases (GSTs) are important carcinogen-metabolizing enzymes. Polymorphisms involved in these enzymes can modulate the development and treatment of head and neck cancer. To investigate the association of GSTs polymorphisms with head and neck cancer and risk factors, clinical-pathological features, and survival time of the patients treated with chemotherapy and/or radiotherapy. Methods: The GST gene polymorphisms were evaluated in 197 cases and 514 controls by PCR-RFLP-Polymerase Chain Reaction Restriction Fragment Length Polymorphism. Results: The GSTP-313 was associated with a decreased risk for HNSCC (p=0.050). The GSTP1 haplotype analysis revealed a higher frequency of the AC and AT haplotypes in the case group than in the control group (p=0.013 and p=0.019, respectively), and the opposite for G-C haplotype (p = 0.015). Yet, the different combinations between the genotypes were associated with an increased risk of cancer. The study showed no association between the polymorphisms and primary tumor site, clinical-pathological characteristics, treatment (chemotherapy and/or radiotherapy) and survival time of the patients. Conclusion: The GST polymorphisms combination showed an increased risk for carcinogenesis, and studies with larger casuistry can contribute to the clarification of the role in individual patient differences for the response to chemotherapy and/or radiotherapy and identify biomarkers of susceptibility. 相似文献
7.
8.
Priya S. Shankarappa Cody J. Peer Arman Odabas Cynthia L. McCully Rafael C. Garcia William D. Figg Katherine E. Warren 《Cancer chemotherapy and pharmacology》2020,85(5):1003-1007
Pexidartinib (PLX3397) is a colony-stimulating factor-1 receptor (CSF-1R) inhibitor under clinical evaluation for potential CNS tumor treatment. This study aims to evaluate plasma pharmacokinetic parameters and estimate CNS penetrance of pexidartinib in a non-human primate (NHP) cerebrospinal fluid (CSF) reservoir model. Five male rhesus macaques, each with a previously implanted subcutaneous CSF ventricular reservoir and central venous lines, were used. NHPs received a single dose of 40 mg/kg pexidartinib (human equivalent dose of 800 mg/m2), administered orally as 200 mg tablets. Serial paired samples of blood and CSF were collected at 0–8, 24, 48, and 72 h. Pexidartinib concentrations were assayed by Integrated Analytical Solutions, Inc. (Berkeley, CA, USA) using HPLC/MS/MS. Pharmacokinetic (PK) analysis was performed using noncompartmental methods. Samples from four NHPs were evaluable. Average (± SD) plasma PK parameters were as follows: Cmax = 16.50 (± 6.67) μg/mL; Tmax = 5.00 (± 2.58) h; AUClast = 250.25 (± 103.76) h*μg/mL; CL = 0.18 (± 0.10) L/h/kg. In CSF, pexidartinib was either quantifiable (n = 2), with Cmax values of 16.1 and 10.1 ng/mL achieved 2–4 h after plasma Tmax, or undetected at all time points (n = 2, LLOQCSF = 5 ng/mL). Pexidartinib was well-tolerated in NHPs, with no Grade 3 or Grade 4 toxicities. The CSF penetration of pexidartinib after single-dose oral administration to NHPs was limited. 相似文献
9.
10.